Tumor immunotherapy by epicutaneous immunization requires Langerhans cells

Journal of Immunology

Volumn 180, Issue 3, 2008, Pages 1991-1998

  Stoitzner, Patrizia ^a,b   Green, Laura K ^a   Jung, Jae Y ^a   Price, Kylie M ^a   Tripp, Christoph H ^b   Malissen, Bernard ^c   Kissenpfennig, Adrien ^c,d   Hermans, Ian F ^a   Ronchese, Franca ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c INSERM   (France)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; OVALBUMIN; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL KILLING; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; IMMUNOPROPHYLAXIS; LANGERHANS CELL; MELANOMA; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; CYTOLOGY; IMMUNIZATION; IMMUNOLOGY; SKIN; SKIN TUMOR; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; IMMUNIZATION; LANGERHANS CELLS; MELANOMA; MICE; MICE, TRANSGENIC; OVALBUMIN; SKIN; SKIN NEOPLASMS;

EID: 40749154946     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.3.1991     Document Type: Article

References (37)

1. Hermans, I. F., A. Daish, P. Moroni-Rawson, and F. Ronchese. 1997. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol. Immunother. 44: 341-347.
2. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1: 1297-1302.
3. Schuler, G., B. Schuler-Thurner, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15: 138-147.
4. Partidos, C. D., A. S. Beignon, F. Mawas, G. Belliard, J. P. Briand, and S. Muller. 2003. Immunity under the skin: potential application for topical delivery of vaccines. Vaccine 21: 776-780.
5. Warger, T., H. Schild, and G. Rechtsteiner. 2007. Initiation of adaptive immune responses by transcutaneous immunization. Immunol. Lett. 109: 13-20.
6. + T cells. Immunology 105: 204-212.
7. Seo, N., Y. Tokura, T. Nishijima, H. Hashizume, F. Furukawa, and M. Takigawa. 2000. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad. Sci. USA 97: 371-376.
8. Yagi, H., H. Hashizume, T. Horibe, Y. Yoshinari, M. Hata, A. Ohshima, T. Ito, M. Takigawa, A. Shibaki, H. Shimizu, and N. Seo. 2006. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res. 66: 10136-10144.
9. Bennett, C. L., E. van Rijn, S. Jung, K. Inaba, R. M. Steinman, M. L. Kapsenberg, and B. E. Clausen. 2005. Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J. Cell Biol. 169: 569-576.
10. Kissenpfennig, A., S. Henri, B. Dubois, C. Laplace-Builhe, P. Perrin, N. Romani, C. H. Tripp, P. Douillard, L. Leserman, D. Kaiserlian, et al. 2005. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22: 643-654.
11. Kaplan, D. H., M. C. Jenison, S. Saeland, W. D. Shlomchik, and M. J. Shlomchik. 2005. Epidermal Langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 23: 611-620.
12. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
13. Stoitzner, P., C. H. Tripp, P. Douillard, S. Saeland, and N. Romani. 2005. Migratory Langerhans cells in mouse lymph nodes in steady state and inflammation. J. Invest. Dermatol. 125: 116-125.
14. Stoitzner, P., C. H. Tripp, A. Eberhart, K. M. Price, J. Y. Jung, L. Bursch, F. Ronchese, and N. Romani. 2006. Langerhans cells cross-present antigen derived from skin. Proc. Natl. Acad. Sci. USA 103: 7783-7788.
15. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76: 34-40.
16. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27.
17. Lugade, A. A., J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174: 7516-7523.
18. Lyons, A. B. 2000. Analyzing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J. Immunol. Methods 243: 147-154.
19. Hermans, I. F., J. D. Silk, J. Yang, M. J. Palmowski, U. Gileadi, C. McCarthy, M. Salio, F. Ronchese, and V. Cerundolo. 2004. The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J. Immunol. Methods 285: 25-40.
20. Lee, A., K. J. Farrand, N. Dickgreber, C. M. Hayman, S. Jurs, I. F. Hermans, and G. F. Painter. 2006. Novel synthesis of α-galactosyl- ceramides and confirmation of their powerful NKT cell agonist activity. Carbohydr. Res. 341: 2785-2798.
21. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171: 5140-5147.
22. McLellan, A. D., G. C. Starling, and D. N. Hart. 1995. Isolation of human blood dendritic cells by discontinuous Nycodenz gradient centrifugation. J. Immunol. Methods 184: 81-89.
23. Douillard, P., P. Stoitzner, C. H. Tripp, V. Clair-Moninot, S. Ait-Yahia, A. D. McLellan, A. Eggert, N. Romani, and S. Saeland. 2005. Mouse lymphoid tissue contains distinct subsets of langerin/CD207 dendritic cells, only one of which represents epidermal-derived Langerhans cells. J. Invest. Dermatol. 125: 983-994.
24. Grabbe, S., S. Bruvers, R. L. Gallo, T. L. Knisely, R. Nazareno, and R. D. Granstein. 1991. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146: 3656-3661.
25. Rechtsteiner, G., T. Warger, P. Osterloh, H. Schild, and M. P. Radsak. 2005. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J. Immunol. 174: 2476-2480.
26. Holzmann, S., C. H. Tripp, M. Schmuth, K. Janke, F. Koch, S. Saeland, P. Stoitzner, and N. Romani. 2004. A model system using tape stripping for characterization of Langerhans cell-precursors in vivo. J. Invest. Dermatol. 122: 1165-1174.
27. Dunn, G. P., C. M. Koebel, and R. D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6: 836-848.
28. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161: 897-908.
29. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
30. Glenn, G. M., D. N. Taylor, X. Li, S. Frankel, A. Montemarano, and C. R. Alving. 2000. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6: 1403-1406.
31. Glenn, G. M., T. Scharton-Kersten, R. Vassell, C. P. Mallett, T. L. Hale, and C. R. Alving. 1998. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161: 3211-3214.
32. Suzuki, H., B. Wang, G. M. Shivji, P. Toto, P. Amerio, M. A. Tomai, R. L. Miller, and D. N. Sauder. 2000. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J. Invest. Dermatol. 114: 135-141.
33. Flacher, V., M. Bouschbacher, E. Verronese, C. Massacrier, V. Sisirak, O. Berthier-Vergnes, B. de Saint-Vis, C. Caux, C. Dezutter-Dambuyant, S. Lebecque, and J. Valladeau. 2006. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol. 177: 7959-7967.
34. Mitsui, H., T. Watanabe, H. Saeki, K. Mori, H. Fujita, Y. Tada, A. Asahina, K. Nakamura, and K. Tamaki. 2004. Differential expression and function of Toll-like receptors in Langerhans cells: comparison with splenic dendritic cells. J. Invest. Dermatol. 122: 95-102.
35. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6: 769-776.
36. Schuler, G., and R. M. Steinman. 1985. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J. Exp. Med. 161: 526-546.
37. + dendritic cells but not by Langerhans cells. Science 301: 1925-1928.